https://www.selleckchem.com/pr....oducts/incb084550.ht
Patient-reported outcomes among survivors of pediatric hematopoietic stem cell transplant (HSCT) are understudied. We compared symptom prevalence, health-related quality of life (HRQOL), and risk factors in adult survivors of childhood hematologic malignancies treated with HSCT to those treated with conventional therapy and non-cancer controls. Survivors of childhood hematologic malignancies (HSCT N=112 [70% allogeneic, 30% autologous]; conventionally-treated N=1,106) and non-cancer controls (N=242) from the St. Jude Lifetime Cohort
Like
Comment
Share
